相关实验视频

Updated: Aug 7, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

新辅助化疗前后的突变谱三阴性乳腺癌的突变谱

Adriana Aguilar-Mahecha¹, Najmeh Alirezaie², Josiane Lafleur¹

¹Cancer Genomics and Translational Research Laboratory, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.

|January 23, 2024

概括

化疗在三阴性乳腺癌 (TNBC) 中引起了适度的基因组变化. 特定基因的突变与化学抵抗或敏感性相关,影响患者的结果.

科学领域:

基因组学就是基因组学.
在瘤学瘤学.
分子生物学分子生物学

背景情况:

对新辅助化疗的三阴性乳腺癌 (TNBC) 反应显著影响患者的预后.
了解化疗诱导的基因组变化对于识别耐药性和敏感性机制至关重要.

研究的目的:

为了研究新辅助化疗对TNBC患者瘤基因组的影响.
为了确定与化学抵抗和化学敏感性相关的特定突变.

主要方法:

在化疗前后的瘤样本和来自26名TNBC患者的匹配淋巴细胞上进行了整体外基因组测序.
分析的重点是瘤间异质性,克隆进化和突变频谱差异.

主要成果:

观察到显著的瘤间异质性与有限的复发突变超出TP53.
在化疗前和后的瘤之间观察到最小的基因组进化,类似的基因组为突变 (例如神经发生相关的基因) 进行了丰富.
显著的基因突变与化学敏感性 (例如,COL1A2,APOBEC3B,PALB2) 和耐化学性 (例如,BRCA1,ATR,ARID1A) 瘤有关.

结论:

化疗诱导TNBC中适度的基因组不稳定性,主要是通过单核酸变异.
化疗后瘤的突变特征更类似于转移样本.
识别与治疗反应相关的特定突变可以为TNBC的未来治疗策略提供信息.

关键词:

化学电阻是一种化学电阻.化学疗法化疗化疗外基因组测序是指外基因组的测序.基因组学就是基因组学.突变是发生在突变中的突变.三重阴性乳腺癌是什么

更多相关视频

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...